18 results
8-K
EX-3.2
PNT
POINT Biopharma Global Inc.
27 Dec 23
Termination of a Material Definitive Agreement
8:54am
reasonable, documented and out-of-pocket attorneys’ fees, retainers, court costs, transcript costs, fees of expert witnesses, private investigators
DEF 14A
PNT
POINT Biopharma Global Inc.
28 Apr 22
Definitive proxy
8:36am
Goodman and David Lubner is financially literate and Ms. Gilmour qualifies as an “audit committee financial expert” as defined in applicable SEC rules … the applicable rules and regulations of the SEC and Nasdaq. The Board has designated Margaret E. Gilmour as an “audit committee financial expert
424B3
PNT
POINT Biopharma Global Inc.
31 Mar 22
Prospectus supplement
11:42am
and is "financially literate" as required by the rules of Nasdaq. Ms. Gilmour qualifies as an “audit committee financial expert” as defined
POS AM
PNT
POINT Biopharma Global Inc.
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
. Ms. Gilmour qualifies as an “audit committee financial expert” as defined in applicable SEC rules.
Compensation Committee
The members of our
424B3
3tvt0cc6bo k2ru
5 Aug 21
Prospectus supplement
4:26pm
8-K
EX-10.18
kdoe8fbipo3z2ibr
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
8-K
EX-3.2
95247
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
8-K/A
EX-2.1
uic5e2pae x2
18 Mar 21
Financial Statements and Exhibits
9:08am
10-K
wv3if
5 Mar 21
Annual report
8:13am
424B4
tqggvtvnbtufx6node
9 Jul 20
Prospectus supplement with pricing info
4:46pm
S-1
f5m kmz71e9
15 Jun 20
IPO registration
5:28pm
DRS
1qjpj0e7wkh2cia
14 May 20
Draft registration statement
12:00am
- Prev
- 1
- Next